Pay in 4 interest-free payments of $6.04 Learn more
Ships within 48 hours · Estimated delivery Nov 6 - Nov 11
FDA Removes GHK-Cu from Category 2: What Peptide Users Need to Know On April 15, 2026, the FDA announced a significant regulatory update: injectable GHK-Cu (copper tripeptide-1) will be removed from the Category 2 bulk substances list by July 2026
Large amounts of TG cannot be cleared and IR-induced hyperinsulinemia inhibits apolipoprotein B100 synthesis and reduces very low-density lipoprotein (VLDL) related lipid output from hepatocytes (32)
Tong (Purdue University) for imaging assistance
As more peptide and bRo5 programs move into late development, drug delivery strategy is becoming a primary design axis, not a downstream activity
US$ 28.33
US$ 22.24
US$ 26.67
US$ 26.43
